Hiroki Kitaoka
I had the opportunity to participate in the FAOPS Congress held in Seoul, Korea. This was my first time attending FAOPS overseas, making it a valuable experience. Recently, South Korea approved insurance coverage for inhaled nitric oxide (iNO) therapy for newborns, which made the sessions on iNO therapy particularly insightful. One session, in particular, provided detailed insights into Australia's experience with iNO, which was extremely informative. Since I am involved in developing guidelines for iNO therapy on premature infants with the Japan Society for Neonatal Health and Development, I found it highly beneficial to learn about the status of iNO therapy in Asia and Oceania. This knowledge will undoubtedly contribute to the advancement of neonatal care in Japan.
I also had the opportunity to present a poster on a systematic review of the effects of furosemide during COX inhibitor therapy for patent ductus arteriosus. This presentation also reflected the part of guidelines development with the Japan Society for Neonatal Health and Development, and it was a great chance to share our work with an international audience. Overall, this congress provided not only new insights into neonatal therapies but also a platform to showcase Japan's contributions to neonatal health on a global stage.